MFN2

Across TCGA pan-cancer cohorts, MFN2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MFN2 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MFN2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MFN2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where MFN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.235	0.887	.005	48	view →
GBM	DFS	Tertile	All	0.825	0.594	.009	9	view →
LUAD	OS	Tertile	III,IV	0.395	0.819	.022	7	view →
UCEC	DFS	Median	II,III,IV	0.487	0.873	.019	4	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.855	.021	4	view →
PDAC	OS	Median	II,III,IV	0.950	0.714	.003	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MFN2–CCRCC (DFS)

Open the CCRCC breakdown →